PepsiCo is set to release its third-quarter earnings on Thursday, and investors are watching closely to see whether the company's North American snacks-and-soda business is stabilizing. The report comes about a year after activist investor Elliott Investment Management took a roughly $4 billion stake in the company, promising a turnaround. Now, that plan is being tested by two powerful forces: the rising use of weight-loss drugs and higher input costs.
What's on investors' minds
The key metrics to watch are North America volumes and margins. Volumes—the number of products sold—have been under pressure as consumers, particularly in the U.S., cut back on salty snacks and sugary drinks. Some of that slowdown is linked to the growing popularity of GLP-1 drugs, which suppress appetite and are used for diabetes and weight loss. As more people take these medications, demand for indulgent foods could weaken further.
At the same time, PepsiCo has been dealing with higher costs for ingredients, packaging, and transportation. These expenses have squeezed margins, making it harder for the company to maintain profitability while keeping prices competitive. Investors want to see whether management can navigate these headwinds and deliver on the growth targets that Elliott's involvement helped set.
The Elliott factor
Elliott Investment Management is known for taking large stakes in companies and pushing for changes to boost shareholder value. When it invested in PepsiCo last year, the market expected a renewed focus on efficiency and cost discipline. The activist's presence often signals that management will be held to a higher standard, with an emphasis on operational improvements and capital allocation.
Since then, PepsiCo has taken steps to streamline its business, but the external environment has not been cooperative. The snack and beverage giant faces a mature market in North America, where growth is hard to come by. International markets offer more opportunity, but they also come with currency fluctuations and geopolitical risks.
What this means for investors
For everyday investors, Thursday's report is more than just a quarterly update. It's a test of whether PepsiCo can adapt to changing consumer habits and rising costs without sacrificing growth. If volumes continue to decline, it could signal that the company's core products are losing their appeal. If margins shrink, it might indicate that pricing power is weakening.
Investors should also consider the broader context. The company's performance is often seen as a bellwether for the consumer staples sector. A weak report could weigh on other food and beverage stocks, while a strong one might reassure the market that these companies can weather the storm.
It's also worth noting that Treasury yields have been easing recently, which can affect the valuation of dividend-paying stocks like PepsiCo. Lower yields make these stocks more attractive relative to bonds, but they also reflect expectations about the economy and inflation.
Looking ahead
Beyond the numbers, investors will listen for management's guidance on the rest of the year. Will they reaffirm their full-year targets, or will they lower them? Any commentary on the impact of GLP-1 drugs on consumer behavior will be closely parsed. The company may also discuss its pricing strategy and how it plans to manage costs.
PepsiCo is not alone in facing these challenges. Other consumer giants are also grappling with the same trends. For instance, luxury brands are seeing a slowdown in demand, though for different reasons. The broader picture is one of cautious consumers and rising costs across many sectors.
The bottom line
Thursday's earnings will give investors a clearer picture of whether PepsiCo's turnaround is on track. The company has a strong portfolio of brands and a global footprint, but it must adapt to a changing consumer landscape. The rise of GLP-1 drugs is a structural shift that could have long-term implications for the food industry. Higher costs are a more immediate challenge that requires careful management.
For now, the market is waiting. The stock's reaction to the report will depend on how the numbers compare to expectations and what management says about the future. As always, it's important for investors to focus on the long-term fundamentals rather than short-term price moves.
